Table 2 Demographics of patients undergoing surgical resection of primary lung tumors classified by ABT requirements
Patient demographics at study entry | Control group (no ABT) n = 469 | ABT group n = 60 | p value |
|---|---|---|---|
Age (median, quartiles [1st; 3rd]) years | 67.03 [59.3; 73.2] | 66.7 [60.3; 72.3] | 0.8436 |
Sex (n, %) | |||
Female | 202/469 (43.1%) | 31/60 (51.7%) | 0.2066 |
Male | 267/469 (56.9%) | 29/60 (48.3%) | |
BMI (median, quartiles [1st; 3rd]) | 26.1 [23.4; 29.4] | 24.6 [21.1; 27.6] | 0.0066 |
BMI < 18.5 kg/m2 (n, %) | 14/451 (3.1%) | 5/59 (8.5%) | 0.0566 |
BMI > 30 kg/m2 (n, %) | 104/451 (23.1%) | 8/59 (13.6%) | 0.0974 |
Comorbidities (n, %) | |||
Respiratory | 186/467 (39.8%) | 29/59 (49.2%) | 0.1698 |
Cardiovascular | 149/467 (31.9%) | 19/59 (32.2%) | 0.9632 |
Renal | 28/467 (6.0%) | 7/59 (11.9%) | 0.0967 |
Liver | 16/467 (3.4%) | 2/59 (3.4%) | 1.0 |
Neurological | 58/467 (12.4%) | 8/59 (13.6%) | 0.8034 |
Diabetes mellitus | 50/467 (10.7%) | 5/59 (8.5%) | 0.5975 |
Non-pulmonary malignancies | 69/467 (14.8%) | 13/59 (22.0%) | 0.1476 |
Coagulation disorders | 3/467 (0.6%) | 0/59 (0.0%) | 1.0 |
No. of comorbidities > 1 | 167/469 (35.6%) | 26/60 (43.3%) | 0.2418 |
Previous treatments (n, %) | |||
Previous thoracic surgery | 18/458 (3.9%) | 1/57 (1.8%) | 0.7097 |
Neoadjuvant chemotherapy | 24/467 (5.1%) | 11/59 (18.6%) | 0.0007 |
Preoperative anticoagulation | 179/467 (38.3%) | 25/59 (42.4%) | 0.5481 |
Lung function parameters (median, quartiles [1st; 3rd]) | |||
VC (predicted, %) | 0.94 [0.83–1.04] | 0.86 [0.73–0.96] | 0.0013 |
FEV1 (predicted, %) | 0.77 [0.69–0.84] | 0.76 [0.68–0.86] | 0.9262 |
DLCO (predicted, %) | 0.73 [0.60–0.84] | 0.55 [0.47–0.74] | < 0.0001 |
Tumor size (median, quartiles [1st; 3rd]) cm | 3.10 [2.10–4.50] | 4.50 [2.60–6.80] | 0.0011 |
> 3 cm (n, %) | 252/469 (53.7%) | 44/60 (73.3%) | 0.0039 |
Tumor side (n, %) | |||
Left | 204/469 (43.5%) | 29/60 (48.3%) | 0.4774 |
Right | 265/469 (56.5%) | 31/60 (51.7%) | |
Tumor localization (n, %) | |||
Left upper lobe | 108/469 (23.0%) | 14/60 (23.3%) | 0.7197 |
Left lower lobe | 73/469 (15.6%) | 8/60 (13.3%) | 0.7197 |
Right upper lobe | 134/469 (28.6%) | 15/60 (25.0%) | 0.4884 |
Middle lobe | 42/469 (9.0%) | 5/60 (8.3%) | 0.5859 |
Right lower lobe | 88/469 (18.8%) | 9/60(15.0%) | 0.8921 |
Histological features of primary tumor (WHO 2015) (n, %) | |||
Non-small cell lung cancer | 465/469 (99.1%) | 60/60 (100%) | 1.0 |
Adenocarcinoma | 260/469 (55.4%) | 22/60 (36.7%) | 0.0060 |
G1 lepidic | 22/469 (4.7%) | 0/60 (0%) | 0.2350 |
G2 acinar/papilar | 153/469 (32.6%) | 11/60 (18.3%) | 0.4193 |
G3 micropapilar/solide | 81/469 (17.3%) | 9/60 (15.0%) | 0.3459 |
Undifferentiated | 4/469 (0.9%) | 2/60 (3.3%) | 0.0720 |
Squamous-cell carcinoma | 122/469 (26.0%) | 27/60 (45.0%) | 0.0021 |
Keratinized | 57/469 (12.2%) | 16/60 (26.7%) | 0.2150 |
Non-keratinized | 60/469 (12.8%) | 8/60 (13.3%) | |
Basaloid | 2/469 (0.4%) | 1/60 (1.7%) | |
Carcinoid | 53/469 (11.3%) | 2/60 (3.3%) | 0.0569 |
Typical | 47/469 (10.0%) | 2/60 (3.3%) | |
Atypical | 6/469 (1.3%) | 0/60 (0%) | |
Large-cell | 21/469 (4.5%) | 3/60 (5.0%) | 0.7456 |
Others | 9/469 (1.9%) | 6/60 (10.0%) | 0.0037 |
Small cell lung cancer | 4/469 (0.9%) | 0/60 (0%) | 1.0 |
TNM7 classification (n, %) | |||
T0 | 2/469 (0.4%) | 1/60 (1.7%) | 0.3036 |
T1 | 181/469 (38.6%) | 8/60 (13.3%) | 0.0001 |
T2 | 203/469 (43.3%) | 24/60 (40.0%) | 0.6285 |
T3 | 70/469 (14.9%) | 24/60 (40.0%) | < 0.0001 |
T4 | 13/469 (2.8%) | 3/60 (5.0%) | 0.4100 |
Lymph node involvement (n, %) | |||
N0 | 319/469 (68.0%) | 36/60 (60.0%) | 0.2803 |
N1 | 64/469 (13.6%) | 14/60 (23.3%) | 0.0037 |
N2 | 84/469 (17.9%) | 9/60 (15.00%) | 0.6137 |
N3 | 2/469 (0.4%) | 0/60 (0%) | 1.0 |
Unknown | 0/469 (0%) | 1/60 (1.7%) | 1.0 |